Drugs / Fluzoparib
Fluzoparib
Trials 97 · started per year
today
1
3
3
2
10
13
12
7
20
14
7
5
2015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 123 trials | ||||||
| Phase 1 | NCT05440006 | Jul 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05032235 | Nov 2021 → Dec 2023 | impaired renal function disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04718740 | Jun 2021 → Oct 2022 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04694365 | Mar 2021 → Jun 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04425876 | Dec 2020 → Mar 2023 | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04333134 | Apr → May 2020 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04341077 | Apr 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04108247 | Sep 2019 → Jun 2023 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04041011 | Sep 2019 → Apr 2021 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04108676 | Sep 2019 | neoplastic disease or syndrome | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04011124 | Jul → Sep 2019 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04193319 | Jul → Sep 2019 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04013048 | Jul → Dec 2019 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03645200 | Jul → Dec 2019 | cancer of unknown primary site | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03945604 | Jun 2019 → Feb 2021 | triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03509636 | Apr 2018 → Aug 2019 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03182673 | Jul 2017 → Jun 2019 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT03075462 | Mar 2017 → Aug 2021 | ovarian cancer, triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03026881 | Jan 2017 → Apr 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03062982 | Dec 2016 → Jan 2017 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02747342 | Sep 2016 → Jun 2019 | prostate cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02759666 | Jun 2016 → Mar 2019 | neoplasm | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02575651 | Apr 2015 → Jun 2018 | high grade malignant neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07141771 | Dec 2025 → Jun 2030 expected | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06208410 | Jan 2024 → Feb 2027 expected | neoplasm | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05983237 | Aug 2023 → Dec 2026 expected | melanoma | Jun Guo | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05928780 | Jul 2023 → Mar 2024 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04659785 | Jul 2020 → Jul 2021 | small cell lung carcinoma | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04518501 | Jul 2020 → Dec 2024 overdue | — | Xing Xie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04400188 | Jun 2020 → Jan 2022 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04228601 | Jan 2020 → Aug 2022 | pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 251 trials | ||||||
| Phase 2 | NCT07647653 | Jun 2026 → Feb 2031 expected | ovarian cancer | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07353437 | Mar 2026 → Dec 2031 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07382713 | Feb 2026 → Dec 2030 expected | ovarian cancer | Jinhua Zhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07321015 | Jan 2026 → Nov 2027 expected | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07339553 | Jan 2026 → Jan 2029 expected | ovarian carcinoma | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07355010 | Dec 2025 → Dec 2028 expected | ovarian cancer | Qinglei Gao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07047066 | Jul 2025 → Jul 2026 overdue | glioblastoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07033819 | Jun 2025 → Jun 2027 expected | ovarian carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06827717 | Apr 2025 → Apr 2027 expected | Ewing sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06971211 | Nov 2024 → Oct 2027 expected | castration-resistant prostate carcinoma | Jianbin Bi | Recruiting | No outcome recorded |
| Phase 2 | NCT06735326 | Nov 2024 → Aug 2026 overdue | fallopian tube cancer, ovarian cancer, peritoneum cancer | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 2 | NCT06552858 | Sep 2024 → Sep 2026 expected | ovarian cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06561022 | Aug 2024 → Dec 2025 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06541314 | Jun 2024 → May 2026 | ovarian cancer | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT06446206 | Jun 2024 → Jun 2026 overdue | — | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06413992 | May 2024 → Jun 2026 overdue | endometrial carcinoma, metastatic carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06254066 | Apr 2024 → Sep 2026 expected | female breast carcinoma, hormone receptor-positive breast cancer | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06161272 | Dec 2023 → Mar 2025 | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT06055166 | Nov 2023 → Nov 2024 | — | Chongqing University Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06081595 | Oct 2023 → Dec 2024 overdue | — | Jin Li | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06063070 | Oct 2023 → Jan 2025 overdue | fallopian tube cancer, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05753826 | Aug 2023 → Dec 2025 overdue | ovarian cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05585281 | Jul 2023 → Nov 2025 | ovarian cancer | Yongpeng Wang | Unknown | No outcome recorded |
| Phase 2 | NCT05952128 | Jul 2023 → Dec 2024 | sarcoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05932264 | Jul 2023 → Jul 2024 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05894018 | Jun 2023 → Dec 2028 expected | soft tissue sarcoma | Fujun Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT06516445 | Jun 2023 → Jun 2025 overdue | colorectal cancer | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06074692 | Jun 2023 → Aug 2026 overdue | bone sarcoma, soft tissue sarcoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05938374 | May 2023 → Dec 2024 | soft tissue sarcoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT05819060 | Apr 2023 → Sep 2024 | ovarian cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05834582 | Apr 2023 → Jun 2025 | triple-negative breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05732129 | Mar → Nov 2023 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05759546 | Feb 2023 → Nov 2025 overdue | breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05656131 | Nov 2022 → Mar 2026 | Her2-receptor negative breast cancer | wang shusen | Suspended | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05576389 | Oct 2022 → Apr 2024 overdue | Her2-receptor negative breast cancer | Peking University People's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05349409 | Jun 2022 → Nov 2024 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05761470 | May 2022 → Jun 2024 overdue | Her2-receptor negative breast cancer | Ying Lin | Recruiting | No outcome recorded |
| Phase 2 | NCT05170594 | Dec 2021 → Jun 2024 | ovarian cancer | The Second Affiliated Hospital of Shandong First Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04978012 | Jul 2021 → Dec 2024 | nasopharyngeal carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04869488 | Jul 2021 → Feb 2023 | metastatic prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04937972 | Jul 2021 → Dec 2024 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05223582 | May 2021 → Dec 2023 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04828395 | Mar 2021 → Mar 2023 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05085626 | Feb 2021 → Oct 2023 | Her2-receptor negative breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04535687 | Dec 2020 → Jun 2023 | renal cell carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05406999 | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT04102124 | Apr 2019 → Aug 2021 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT06913777 | Apr 2025 → Oct 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06188455 | Dec 2024 → Dec 2025 overdue | ovarian cancer | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06539091 | Oct 2024 → Oct 2025 overdue | malignant epithelial tumor of ovary | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06612814 | Sep 2024 → Oct 2027 expected | breast carcinoma | Zhimin Shao | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06533384 | Aug 2024 → Dec 2026 expected | triple-negative breast carcinoma | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06255392 | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05891093 | Jun 2023 → May 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT04691804 | Mar 2021 → Dec 2026 expected | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04300114 | Aug 2020 → Feb 2022 | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04296370 | Jul 2020 → Jun 2022 | Her2-receptor negative breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04229615 | Jun 2020 → Jun 2023 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03863860 | Apr 2019 → Jan 2022 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07000344 | Jul 2025 → Mar 2026 | ovarian cancer | Peking Union Medical College Hospital | Terminated | No outcome recorded |
| — | NCT04782089 | May 2021 → May 2023 | small cell lung carcinoma | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05479487 Comparator | Aug 2022 → Nov 2023 overdue | — | Xiaohua Wu MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04517357 Comparator | Oct 2020 → Nov 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06954584 Background | May 2025 → May 2030 expected | ovarian cancer | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzoparib | “Fluzoparib: 100 mg orally twice daily, with a 4-week continuous treatment cycle.” NCT07000344 ↗81“Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.” NCT05406999 ↗ “A single oral dose of fluzoparib on Day 1” NCT04341077 ↗ “fluzoparib 150 mg PO bid” NCT06145308 ↗ “SHR-1701 +fluzoparib” NCT04937972 ↗ |
| Known as | Fluzoparib Capsules | “Drug: Fluzoparib Capsules” NCT06188455 ↗ |
| Known as | fuzuloparib | “Phase 2: Zeprumetostat Tablets in Combination with Fuzuloparib Dose: Zeprumetostat Tablets 250 mg, bid, po, Fuzuloparib 100 mg, bid, po.” NCT07339553 ↗9“fuzuloparib (formerly fluzoparib) versus placebo as a maintenance treatment” PMID 35404684 ↗ Apr 2022 |
| Known as | Fuzuopali | ChEMBL registry synonym — accepted as the source's own label CHEMBL3930624 ↗ |
| Known as | HS-10160 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3930624 ↗ |
| Known as | SHR-3162 | “Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.
Other names: SHR-3162” NCT05952128 ↗12“Drug Fluzoparib 50mg PO bid, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle. Other names: SHR-3162.” NCT06827717 ↗ “A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer” NCT04400188 ↗ “A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients” NCT04041011 ↗ “she will receive PARP inhibitor SHR3162 150mg bid” NCT03805399 ↗ |
| Action | Inhibit | “PARP-1 and PARP-2 inhibitor” NCT02575651 ↗ |
| Modality | Small molecule | “Fluzoparib (SHR-3162) is an orally available, small molecule inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 1/2 being developed for treatment of...” NCT03509636 ↗ |
| Route | Oral | “when given orally to Chinese patients with advanced solid malignancies” NCT02575651 ↗ |